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Purpose: To evaluate the safety and efﬁcacy of dexamethasone intravitreal implant (Ozurdex, DEX implant)
0.7 and 0.35 mg in the treatment of patients with diabetic macular edema (DME).
Design: Two randomized, multicenter, masked, sham-controlled, phase III clinical trials with identical pro-
tocols were conducted. Data were pooled for analysis.
Participants: Patients (n ¼ 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen
equivalent, and central retinal thickness (CRT) of 300 mm by optical coherence tomography.
Methods: Patientswere randomized ina1:1:1 ratio to study treatmentwithDEX implant 0.7mg,DEX implant 0.35
mg,or shamprocedureand followed for3 years (or 39months forpatients treatedatmonth36) at40scheduledvisits.
Patients who met retreatment eligibility criteria could be retreated no more often than every 6 months.
Main Outcome Measures: The predeﬁned primary efﬁcacy endpoint for the United States Food and Drug
Administration was achievement of 15-letter improvement in BCVA from baseline at study end. Safety measures
included adverse events and intraocular pressure (IOP).
Results: Mean number of treatments received over 3 years was 4.1, 4.4, and 3.3 with DEX implant 0.7 mg, DEX
implant 0.35 mg, and sham, respectively. The percentage of patients with 15-letter improvement in BCVA from
baseline at study end was greater with DEX implant 0.7 mg (22.2%) and DEX implant 0.35 mg (18.4%) than sham
(12.0%; P  0.018). Mean average reduction in CRT from baseline was greater with DEX implant 0.7 mg (111.6
mm) and DEX implant 0.35 mg (107.9 mm) than sham (41.9 mm; P < 0.001). Rates of cataract-related adverse
events in phakic eyes were 67.9%, 64.1%, and 20.4% in the DEX implant 0.7 mg, DEX implant 0.35 mg, and sham
groups, respectively. Increases in IOP were usually controlled with medication or no therapy; only 2 patients (0.6%)
in the DEX implant 0.7 mg group and 1 (0.3%) in the DEX implant 0.35 mg group required trabeculectomy.
Conclusions: The DEX implant 0.7 mg and 0.35 mg met the primary efﬁcacy endpoint for improvement in
BCVA. The safety proﬁle was acceptable and consistent with previous reports. Ophthalmology 2014;121:1904-
1914 ª 2014 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Supplemental material is available at www.aaojournal.org.Diabetic retinopathy (DR) is a leading cause of vision loss
and blindness in adults 40 years of age in the United
States.1 The vision loss associated with DR most commonly
results from diabetic macular edema (DME), which is
estimated to affect 20% of patients with DR.2 Diabetic
macular edema is characterized by capillary leakage,
ﬂuid accumulation, and macular thickening following
breakdown of the blooderetinal barrier.3 Inﬂammation has
an important role in the pathogenesis of DME, because the
breakdown of the blooderetinal barrier involves expression
of inﬂammatory factors4 including vascular endothelial
growth factor (VEGF), intercellular adhesion molecule-1,
interleukin-6, and monocyte chemotactic protein-1, as well
as leukostasis5 and alterations in endothelial tight junction
proteins.61904  2014 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). Published by Elsevier IncFor>25years, standard care forDMEhas includedmedical
control of diabetes (glycemic and blood pressure control, and
lipid management) and focal/grid laser photocoagulation of
leaking microaneurysms and areas of diffuse capillary bed
leakage.7 Laser photocoagulation can reduce the risk of
moderate vision loss in DME, but most patients do not regain
visual acuity that has been lost.8e10 In 2012, the VEGF in-
hibitor ranibizumab became the ﬁrst approved medical treat-
ment for DME. In phase III clinical studies (RISE and
RIDE),11,12 monthly injections of ranibizumab led to a 2- to 3-
fold increase in the percentage of patients who met visual
improvement endpoints compared with sham treatment.
However, the need for frequent injections is a treatment burden
for patients; not all patientswould beable topresent to the clinic
on a monthly basis for 3 years. Furthermore, some patients are.
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RISE and RIDE studies, after 2 years of monthly ranibizumab
injections, pronounced macular edema (evidenced by center-
point thickness of>250 mm on optical coherence tomography
[OCT]) persisted in approximately 23%of patients, and 40%of
patients had not achieved a best-corrected visual acuity
(BCVA) of 20/40.11 Therefore, there remains a need for
additional treatment options for patients with DME.
Intravitreal corticosteroids may be useful in the treatment of
DME because they block production of VEGF and other in-
ﬂammatory mediators,14 inhibit leukostasis,15 and enhance the
barrier function of vascular endothelial cell tight junctions.16
Off-label treatment with intravitreal triamcinolone acetonide
(TA) has been shown to be more effective than placebo in
improving vision in patients with refractory DME.17 The
Diabetic Retinopathy Clinical Research Network (DRCR.net)
Protocol I study evaluating intravitreal TA or ranibizumab in
combination with laser treatment reported similar efﬁcacy of
TA and ranibizumab in pseudophakic eyes, in which there is
no confounding of cataract development associated with
corticosteroid treatment.18
Sustained-release corticosteroids have been developed to
reduce the need for frequent intraocular injections. Dexa-
methasone intravitreal implant (DEX implant; Ozurdex;
Allergan, Inc, Irvine, CA) is a sustained-release biode-
gradable implant approved for treatment of macular edema
related to retinal vein occlusion, as well as noninfectious
posterior segment uveitis. The DEX implant releases the
potent corticosteroid dexamethasone into the vitreous over a
period of 6 months.19 Dexamethasone differs from TA in
pharmacologic activity and lipid solubility, as well as
delivery requirements.20 In previous studies, the DEX
implant has demonstrated efﬁcacy in the treatment of
persistent DME,21,22 DME resistant to anti-VEGF treat-
ment,23 and DME in difﬁcult-to-treat vitrectomized eyes.24
Two large, multicenter clinical trials evaluating the safety
and efﬁcacy of DEX implant 0.7 and 0.35 mg in patients
with DME were designed and conducted to support regu-
latory approval of DEX implant for treatment of DME. We
report here the 3-year results of those trials.
Methods
Study Design
Two randomized, multicenter, masked, sham-controlled, 3-year,
phase III clinical trials (registered with the identiﬁers NCT00168337
and NCT00168389 at ClinicalTrials.gov) evaluated the efﬁcacy and
safety of the DEX implant for treatment of DME. The trials were
conducted from February 2005 to June 2012 at 131 sites in 22
countries. Because the trials were identical in study design, the re-
sults were pooled for analysis. The study adhered to the tenets of the
Declaration of Helsinki and was compliant with the Health Insurance
Portability and Accountability Act of 1996. The study protocol was
approved by an institutional review board or independent ethics
committee at each site, and all patients provided written informed
consent.
Study Population
Patients 18 years of age diagnosed with type 1 or 2 diabetes
mellitus who had fovea-involved macular edema that wasassociated with DR and had been previously treated with medical
or laser therapy were enrolled in the study. Treatment-naïve pa-
tients who had refused laser treatment or who, in the opinion of the
investigator, would not beneﬁt from laser treatment were also
enrolled. BCVA in the study eye, measured with the Early Treat-
ment Diabetic Retinopathy Study method, was required to be be-
tween 34 and 68 letters (20/200e20/50), and central retinal
thickness (CRT) in the 1-mm central macular subﬁeld of the study
eye was required to be 300 mm by time domain OCT using the
OCT2 or OCT3 (Stratus OCT, Carl Zeiss Meditec Inc, Dublin, CA)
system.
Key exclusion criteria included uncontrolled diabetes (glyco-
sylated hemoglobin [HbA1c] >10%) or other systemic disease,
treatment with intravitreal anti-VEGF within 3 months of study
entry, treatment with intravitreal triamcinolone within 6 months of
study entry, current use or anticipated use of systemic steroids
during the study, glaucoma or optic nerve head or visual ﬁeld
damage consistent with glaucoma, history of marked steroid-
induced intraocular pressure (IOP) increase, and ocular hyperten-
sion in the study eye characterized by IOP >23 mmHg without
antiglaucoma medication, IOP >21 mmHg treated with 1 anti-
glaucoma medication, or use of 2 antiglaucoma medications.
Patients with aphakia or an anterior chamber intraocular lens in the
study eye, a history of intraocular laser or incisional surgery in the
study eye within 90 days before study entry, a history of pars plana
vitrectomy in the study eye, or active iris or retinal neo-
vascularization in the study eye were excluded.
If both eyes were eligible for the study, the eye with the
shorter duration of macular edema was selected as the study eye
at the screening visit, and only the study eye received study
treatment.
Randomization, Intervention, and Masking
At the baseline day 0 visit (4e14 days after screening), patients
were randomized in a 1:1:1 ratio to study treatment with DEX
implant 0.7 mg, DEX implant 0.35 mg, or a sham procedure. Each
site used an interactive voice-response or web-response system to
assign randomization numbers to patients. Treatment assignment
was based on enrollment order and a computer-generated
randomization scheme provided by the sponsor. Study treatment
was administered after all baseline evaluations. An applicator
system was used to insert DEX implant into the vitreous of the
study eye through the pars plana as described previously.25 In
the sham procedure, a needleless applicator was pressed against
the conjunctiva of the study eye.25
Each site had a treating investigator who administered the study
treatment and performed postinjection safety evaluations up to day
21 after each treatment. The study personnel who collected efﬁcacy
data, and a follow-up investigator who performed safety evalua-
tions at other study visits, were masked to the treatment assign-
ment, and patients were also masked.
Visit Schedule
Patients were seen at 40 scheduled visits (Fig 1). Study visits
were scheduled every 1.5 months during the ﬁrst year and every
3 months during years 2 and 3. In addition, patients were seen at
safety visits 1, 7, and 21 days after study treatment or
retreatment. After a study protocol amendment in May 2010,
patients who had not yet completed the study and who met
retreatment eligibility criteria were retreated at month 36 and
followed at an additional study visit at month 39. Over 50% of
patients had completed or discontinued the study before the
protocol amendment.1905
Figure 1. Study design and patient ﬂow through the study. *Other reasons for discontinuation included site closure, patient withdrawal of consent, poor
compliance from patient, sponsor request, patient relocation, and patient participation in another trial. AE ¼ adverse event; BCVA ¼ best-corrected visual
acuity; CRT ¼ central retinal thickness; DEX implant ¼ dexamethasone intravitreal implant; DME ¼ diabetic macular edema; OCT ¼ optical coherence
tomography.
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Panretinal photocoagulation for proliferative DR and cataract sur-
gery were allowed at the discretion of the investigator and patient.
All other procedures in the study eye, and all treatments for mac-
ular edema in the study eye with the exception of study treatment,
were prohibited. Systemic treatment with steroids and immuno-
suppressants also was prohibited.
Exit Criteria
A patient could be withdrawn from the study at the patient’s or
investigator’s discretion at any time for any reason. Patients who
received escape therapy (any treatment for macular edema other
than the study treatment) in the study eye were required to be
withdrawn from the study before its administration. Patients who
had a loss of 15 letters in BCVA from baseline in the study eye,
which was conﬁrmed at 2 consecutive visits 4 weeks apart and
was attributed to macular edema, were exited from the study at the
investigator’s discretion.
Retreatment Criteria
Patients were eligible for retreatment with DEX implant only if
there had been 6 months since the most recent study treatment1906and there was evidence of residual edema. For most of the study
(95% of treatments), retreatment eligibility required CRT (retinal
thickness in the 1 mm central macular subﬁeld) of >225 mm by
OCT (as determined by the site), as well as judgment by the
investigator that the treatment would not put the patient at signif-
icant risk. A study protocol amendment in May 2010 revised the
anatomic criterion such that patients with CRT of >175 mm by
OCT or evidence of residual edema on OCT, seen as intraretinal
cysts or regions of retinal thickening within or outside the central
subﬁeld, were eligible for retreatment.
Outcome Measures
Efﬁcacy evaluations included BCVA by the Early Treatment
Diabetic Retinopathy Study method at every study visit, Stratus
OCT2 or OCT3 every 3 months, fundus photography, and ﬂuo-
rescein angiography. The OCT, fundus photography, and ﬂuores-
cein angiography images were evaluated at a central reading center
(University of Wisconsin Fundus Photograph Reading Center,
Madison, WI).
The predeﬁned primary efﬁcacy endpoint for the United States
Food and Drug Administration was the percentage of patients with
BCVA improvement of 15 letters from baseline in the study eye
at the end of the study, with missing values imputed using last
Table 1. Baseline Characteristics of Patients and Study Eyes
Characteristic DEX Implant 0.7 mg (n [ 351) DEX Implant 0.35 mg (n [ 347) Sham (n [ 350)
Mean age (SD), y 62.5 (8.3) 62.3 (9.2) 62.5 (9.5)
Range (y) 33e85 25e84 26e88
Male, n (%) 213 (60.7) 206 (59.4) 217 (62.0)
Mean duration of diabetes (SD), y 16.5 (9.0) 15.8 (9.4) 15.9 (9.1)
Mean HbA1c (SD), % 7.6 (1.2) 7.5 (1.1) 7.5 (1.1)
8%, n (%) 233 (66.4) 237 (68.3) 249 (71.1)
>8%, n (%) 114 (32.5) 108 (31.1) 100 (28.6)
Not available 4 (1.1) 2 (0.6) 1 (0.3)
Mean ETDRS letter score (SD) 56.1 (9.9) 55.5 (9.7) 56.9 (8.7)
Mean CRT (SD), mm 463.0 (157.1) 466.8 (159.5) 460.9 (132.6)
Mean duration of DME (SD), mo 23.6 (26.0) 25.2 (31.4) 25.9 (27.3)
Range (mo) 0e163 0e299 0e187
Previous treatment for DME, n (%)
Focal/grid laser 231 (65.8) 224 (64.6) 243 (69.4)
Intravitreal steroid 58 (16.5) 69 (19.9) 61 (17.4)
Anti-VEGF 25 (7.1) 39 (11.2) 26 (7.4)
None 104 (29.6) 98 (28.2) 89 (25.4)
Severity of NPDR, n (%)
Moderate or better 173 (49.3) 170 (49.0) 174 (49.7)
Severe or worse 151 (43.0) 151 (43.5) 149 (42.6)
Not available 27 (7.7) 26 (7.5) 27 (7.7)
DME perfusion status, n (%)
Ischemic 43 (12.3) 31 (8.9) 27 (7.7)
Nonischemic 257 (73.2) 260 (74.9) 284 (81.1)
Not available 51 (14.5) 56 (16.1) 39 (11.1)
Lens status, n (%)
Phakic 265 (75.5) 259 (74.6) 249 (71.1)
Pseudophakic 86 (24.5) 88 (25.4) 101 (28.9)
Mean IOP (SD), mmHg 15.3 (2.6) 15.6 (2.8) 15.3 (3.1)
Using IOP-lowering medication, n (%) 12 (3.5) 26 (7.6) 14 (4.0)
CRT¼ central retinal thickness; DEX implant¼ dexamethasone intravitreal implant; DME¼ diabetic macular edema; ETDRS¼ Early Treatment Diabetic
Retinopathy Study; HbA1c ¼ glycosylated hemoglobin; IOP ¼ intraocular pressure; NPDR ¼ nonproliferative diabetic retinopathy; SD ¼ standard de-
viation; VEGF ¼ vascular endothelial growth factor.
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study eye included average change in BCVA from baseline during
the study determined with the area under the curve (AUC) method,
mean change in BCVA from baseline at each study visit, time to
15-letter improvement in BCVA from baseline, percentage of
patients with BCVA of 20/40 at each study visit, and average
change in CRT from baseline during the study by OCT (AUC
approach).
Safety parameters included adverse events (AEs), IOP, bio-
microscopic and ophthalmoscopic ﬁndings, and measures of dia-
betes control (HbA1c and glomerular ﬁltration rate).
Data Analysis and Statistical Methods
Efﬁcacy outcomes were evaluated in the intent-to-treat population
of all randomized patients. The last-observation-carried-forward
method was used for imputation of missing values, except in
the analyses of average change in BCVA and CRT from baseline
during the study (AUC approach) and time-to-event data, which
used observed data. Analysis of the proportion of patients with
BCVA improvement of 15 letters from baseline and the pro-
portion of patients with BCVA of 20/40 used the Cochran-
Mantel-Haenszel general association test stratiﬁed by study.
Analysis of the average change in BCVA or CRT from baseline
during the study (AUC approach) used an analysis of covariance
model with treatment and study as ﬁxed effects and baseline
BCVA or CRT as the covariate. Time-to-event data were analyzedwith the Kaplan-Meier method and log-rank tests. Predetermined
subgroup analysis of selected outcome measures was performed
in subgroups of patients deﬁned by demographics, duration of
diabetes, duration of DME, baseline HbA1c, prior laser treatment,
treatment-naïve status, lens status at baseline, and nonproliferative
DR severity at baseline. Safety outcomes were evaluated in the
safety population of all patients who were treated during the
study.
Statistical analysis was performed with SAS version 9.3 (SAS
Inc, Cary, NC) and a 2-sided alpha level of 0.05. The planned
sample size of 510 patients in each trial (170 in each treatment arm)
was estimated to provide 80% power to detect a difference of 10%
between the DEX implant 0.7 mg group and the sham group in the
proportion of patients with 15-letter improvement in BCVA from
baseline, assuming a 5% rate for sham and a 2-sided alpha level of
0.025.Results
A total of 1048 patients were enrolled from February 2005 to June
2009 and randomized to study treatment. There were no differ-
ences in baseline demographic or study eye characteristics among
the treatment groups (Table 1). The mean BCVA in study eyes was
56.2 letters (approximately 20/80 Snellen). The mean duration of
DME before study entry was 24.9 months (median, 16). Overall,
66.6% of patients had received previous laser treatment for1907
Table 2. Number of Study Treatments Received
(Safety Population)
Number of
Study
Treatments
DEX Implant 0.7
mg (n [ 347)
DEX Implant 0.35
mg (n [ 343)
Sham
(n [ 350)
1, n (%) 44 (12.7) 34 (9.9) 106 (30.3)
2, n (%) 54 (15.6) 45 (13.1) 63 (18.0)
3, n (%) 39 (11.2) 41 (12.0) 41 (11.7)
4, n (%) 42 (12.1) 40 (11.7) 26 (7.4)
5, n (%) 49 (14.1) 41 (12.0) 29 (8.3)
6, n (%) 88 (25.4) 105 (30.6) 50 (14.3)
7, n (%) 31 (8.9) 37 (10.8) 35 (10.0)
Mean (SD) 4.1 (2.0) 4.4 (1.9) 3.3 (2.2)
Median 4 5 3
DEX implant ¼ dexamethasone intravitreal implant; SD ¼ standard
deviation.
Figure 2. Primary efﬁcacy endpoint. Percentage of patients with a 15-
letter improvement in best-corrected visual acuity from baseline at the
year 3 or ﬁnal study visit in the intent-to-treat population with last
observation carried forward for missing values. DEX implant ¼ dexa-
methasone intravitreal implant.
Ophthalmology Volume 121, Number 10, October 2014DME, 17.9% had been treated with intravitreal steroid, 8.6% had
been treated with intravitreal anti-VEGF, and 27.8% had
received no previous treatment for DME.
The 3-year study was completed by 607 (57.9%) patients
(Fig 1). Study completion rates were higher in the DEX implant 0.7
mg (64.1%) and 0.35 mg (66.3%) groups than in the sham group
(43.4%) because of a >3-fold higher rate of discontinuations
owing to lack of efﬁcacy in the sham group. The rate of discon-
tinuations owing to AEs was <14% and similar among groups.
The median number of study treatments received by patients was 4
in the DEX implant 0.7 mg group, 5 in the DEX implant 0.35 mg
group, and 3 in the sham group (Table 2). Among patients who
completed the study, the mean number of study treatments
received was 5.0, 5.2, and 5.1 in the DEX implant 0.7 mg, DEX
implant 0.35 mg, and sham groups, respectively.
Efﬁcacy Analyses
The DEX implant 0.7 mg and 0.35 mg demonstrated statistical
superiority to sham in the primary efﬁcacy endpoint (Fig 2). The
percentage of patients with a 15-letter improvement in BCVA
from baseline at the year 3 or ﬁnal study visit was greater with
DEX implant 0.7 mg (22.2%) and DEX implant 0.35 mg (18.4%)
than with sham (12.0%; P  0.018). The interaction of treatment
effect and study was not signiﬁcant (P ¼ 0.853) in the pooled data
analysis, suggesting a consistent effect of treatment across the in-
dividual clinical trials.
A rapid onset of treatment effect compared with sham was
observed in both DEX implant treatment groups. Survival analysis
showed signiﬁcantly earlier gain of 15 letters in BCVA with both
DEX implant 0.7 mg (P < 0.001) and 0.35 mg (P ¼ 0.005)
compared with sham (Fig 3, available at www.aaojournal.org).
Signiﬁcant differences in the proportion of patients with a 15-
letter improvement from baseline were observed between each
DEX implant group and sham as early as day 21 (P  0.003).
The percentage of patients with a 15-letter improvement in
BCVA from baseline, as well as the percentage of patients with
20/40 BCVA, was signiﬁcantly greater in both DEX implant
treatment groups compared with the sham group at the majority of
visits (Fig 4, available at www.aaojournal.org). The mean
(standard deviation) average change in BCVA from baseline
during the study was 3.5 (8.4) letters with DEX implant 0.7 mg,
3.6 (8.1) letters with DEX implant 0.35 mg, and 2.0 (8.0) letters
with sham. The between-group difference in average change in
BCVA from baseline during the study was signiﬁcant for the1908comparison of both DEX implant 0.7 mg (P ¼ 0.023) and DEX
implant 0.35 mg (P ¼ 0.019) with sham.
Analysis of mean change in BCVA from baseline at each study
visit showed greater BCVA improvement in both DEX implant
groups compared with sham at most timepoints during the ﬁrst 15
months. However, the improvement in BCVA provided by DEX
implant relative to sham was reduced after month 15, with a trend
for it to increase and the beneﬁt of DEX implant treatment to
resume in year 3 (Fig 5A). During the second year of the study, an
increase in cataract AE reports correlated with the reduced effect of
treatment.
Because these results suggested that the treatment effect on
vision improvement might be confounded after the ﬁrst year by
cataract formation or progression, additional analyses were per-
formed to take into account the effects of cataract AEs and cataract
surgery on visual acuity. In subgroup analysis, mean improvement
in BCVA provided by DEX implant relative to sham in pseudo-
phakic eyes was consistent across time in the 3-year study, and
there was no reduction in treatment beneﬁt observed in year 2 (Fig
5B). A gain of 15 letters in BCVA from baseline was seen at the
end of the study in 23.3%, 15.9%, and 10.9% of pseudophakic eyes
in the DEX implant 0.7 mg, DEX implant 0.35 mg, and sham
groups, respectively (Table 3). In phakic eyes with an AE report
of cataract, the mean average BCVA improvement from baseline
with DEX implant 0.7 mg was substantial until the time of a
cataract AE report (Fig 6A). Vision loss was observed after an
AE report of cataract until the time of cataract surgery, and
improvement in vision from baseline was restored after cataract
surgery. By the end of the study, treatment with DEX implant
resulted in clinically meaningful improvement in BCVA
independent of the lens status at baseline. The percentage of
patients who gained 15 letters from baseline at study end was
similar in the phakic and pseudophakic subgroups (Fig 7,
available at www.aaojournal.org) and reﬂected the results in the
total study population.
The mean (standard deviation) average reduction in CRT from
baseline during the study was 111.6 (134.1) mm with DEX
implant 0.7 mg, 107.9 (135.8) mm with DEX implant 0.35 mg,
and 41.9 (116.0) mm with sham, and was signiﬁcantly greater
Figure 5. Mean change in best-corrected visual acuity from baseline in (A)
the total study population and (B) the subgroup of patients with pseudo-
phakic study eyes at baseline. Vertical bars indicate the standard error of
the mean. *P  0.046 versus sham (analysis of covariance in the intent-to-
treat population with last-observation-carried-forward imputation of
missing values). DEX implant ¼ dexamethasone intravitreal implant.
Table 3. Efﬁcacy Outcomes in Pseudoph
Parameter
DEX Implant 0.
mg (n [ 86)
Patients with 15 letters BCVA improvement from
baseline at study end, %*
23.3
Time to 15-letter improvement in BCVA from baseline
Cumulative response rate at study end for 15-letter
improvement in BCVA from baseline, %
57.4
Patients with 20/40 BCVA at study end, %* 29.1
Mean (SD) average change in BCVA from baseline across
the study, letters
6.5 (8.1)
Mean (SD) change in BCVA from baseline at study end,
letters*
6.1 (11.5)
Mean (SD) average change in central retinal thickness{
from baseline across the study, mm
131.8 (140.2)
BCVA ¼ best-corrected visual acuity; DEX implant ¼ dexamethasone intravit
*Analysis used the last-observation-carried-forward method for imputation of m
yBased on the Cochran-Mantel-Haenszel general association test stratiﬁed by st
zBased on the log-rank test of cumulative response.
xBased on an analysis of covariance model with treatment and study as factors
kBased on an analysis of covariance model with treatment as factor and the ba
{Retinal thickness in the central retinal subﬁeld by optical coherence tomogra
Boyer et al  Dexamethasone Intravitreal Implant for DMEwith DEX implant 0.7 mg and 0.35 mg than with sham (P <
0.001). Decreases in CRT were seen in eyes that had cataract AEs
leading to cataract surgery, despite the vision loss in those eyes
(Fig 6B). Notably, an increase in CRT after cataract surgery was
observed in the sham group but not in the DEX implant groups
(Fig 6B), suggesting a protective effect of DEX implant
following cataract surgery.
Prespeciﬁed analysis of patient subgroups deﬁned by de-
mographics, diabetes status, duration of diabetes and DME, and
prior treatment, showed effects of DEX implant relative to sham
similar to those in the total study population.
Safety Analyses
The overall incidence of AEs at any time during the study was
96.0% in the DEX implant 0.7 mg group, 97.4% in the DEX
implant 0.35 mg group, and 80.3% in the sham group. These rates
are inﬂuenced by the period of patient exposure to study treatment
(patient years), which was approximately 22% to 24% shorter
in the sham group compared with the DEX implant groups
(853.9 with DEX implant 0.7 mg, 880.2 with DEX implant 0.35
mg, and 665.5 with sham) because of the high rate of discontin-
uations in the sham group during the ﬁrst year of the study
(Fig 1). The overall incidence of AEs adjusted for treatment
exposure time was similar among treatment groups. Almost all
AEs that were considered by the investigator to be possibly
caused by the study treatment occurred in the study eye. Table 4
(available at www.aaojournal.org) lists ocular AEs reported in
2% of the study eyes in any treatment group. The most
common ocular AEs in study eyes were cataract and increased
IOP related to DEX implant.
On biomicroscopy, 85.0% of patients (651/766) with a phakic
study eye had cortical, nuclear, or posterior subcapsular opacities at
baseline. Among patients with a phakic study eye at baseline, the
overall incidence of cataract-related AEs (cataract, cataract cortical,
cataract nuclear, cataract subcapsular, and lenticular opacities) was
67.9%, 64.1%, and 20.4% in the DEX implant 0.7 mg, DEX
implant 0.35 mg, and sham groups, respectively, and the rate of
cataract surgery during the study was 59.2%, 52.3%, and 7.2%,
respectively. The incidence of cataract-related AEs increased afterakic Eyes, Intent-to-Treat Population
7 DEX Implant 0.35
mg (n [ 88)
Sham
(n [ 101)
P Value DEX
Implant 0.7
mg vs Sham
P Value DEX
Implant 0.35
mg vs Sham
15.9 10.9 0.024y 0.329y
43.7 26.3 <0.001z 0.005z
30.7 17.8 0.072 0.042
5.9 (7.1) 1.7 (7.1) <0.001x <0.001x
6.2 (10.6) 1.1 (12.3) 0.004k 0.003k
117.1 (127.1) 50.8 (93.6) <0.001x <0.001x
real implant; SD ¼ standard deviation.
issing values.
udy.
and the baseline value as a covariate.
seline value as a covariate.
phy.
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Figure 6. Mean average change in (A) best-corrected visual acuity (BCVA) and (B) central retinal thickness (CRT) during the study by lens status. Results
were analyzed in phakic patients with a cataract adverse event (AE) as well as in pseudophakic patients using an area-under-the-curve approach and
observed values in the intent-to-treat population. DEX implant ¼ dexamethasone intravitreal implant.
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surgeries in the DEX implant groups were performed between 18
and 30 months.
Approximately one-third of patients in each DEX implant
treatment group had a clinically signiﬁcant increase in IOP requiring
treatment during the study (Table 5). No patient underwent removal
of the implant to control IOP, and only 1 patient (0.3%) in each
DEX implant treatment group underwent glaucoma incisional
surgery for steroid-induced increases in IOP (Table 5). Mean IOP1910peaked at a similar level and returned to baseline levels by 6
months after each DEX implant injection (Fig 8, available at
www.aaojournal.org). Furthermore, in comparison with the
incidence of IOP AEs after the ﬁrst treatment and during the ﬁrst
year of the study, the incidence of IOP AEs did not increase after
subsequent treatments or in year 2 or 3, and the proportion of
patients using IOP-lowering medications in the study eye
remained similar from year to year. Together these results indicate
that there was no cumulative effect of DEX implant on IOP.
Table 7. Incidence of Serious Adverse Events
SAE, n (%)*
DEX Implant 0.7
mg (n [ 347)
DEX Implant 0.35
mg (n [ 343)
Sham
(n [ 350)
Any SAE 115 (33.1) 120 (35.0) 83 (23.7)
Ocular SAE in
study eye
24 (6.9) 14 (4.1) 4 (1.1)
Treatment-related
SAEy
16 (4.6) 10 (2.9) 1 (0.3)
Cataract 8 (2.3) 8 (2.3) 1 (0.3)
Cataract
subcapsular
2 (0.6) 2 (0.6) 0
Table 5. Intraocular Pressure Safety Parameters in Study Eyes
Parameter DEX Implant 0.7 mg (n [ 347) DEX Implant 0.35 mg (n [ 343) Sham (n [ 350)
AE, n (%)* 125 (36.0) 117 (34.1) 18 (5.1)
IOP at any visit during the study, n (%)
25 mmHg 111 (32.0) 94 (27.4) 15 (4.3)
35 mmHg 23 (6.6) 18 (5.2) 3 (0.9)
Increase of 10 mmHg from baseline 96 (27.7) 85 (24.8) 13 (3.7)
Use of IOP-lowering medication, n (%) 144 (41.5) 129 (37.6) 32 (9.1)
Procedure for IOP control, n (%)y
Trabeculectomy 2 (0.6)y 1 (0.3) 0
Iridectomy 1 (0.3) 0 1 (0.3)
Iridotomy 2 (0.6)y 0 0
Trabeculoplasty 0 2 (0.6) 0
AE ¼ adverse event; DEX implant ¼ dexamethasone intravitreal implant; IOP ¼ intraocular pressure.
*Any AE related to elevated IOP or glaucoma.
yOne patient in the DEX implant 0.7 mg group underwent both trabeculectomy and iridotomy; this patient had rubeosis of the anterior chamber angle and
iris and marked anterior chamber ﬁbrin in the study eye that was considered to be the primary cause of the increased IOP.
Boyer et al  Dexamethasone Intravitreal Implant for DMEVitreous hemorrhage in the study eye was reported in 6.9%,
13.1%, and 7.1% of patients in the DEX 0.7 mg, DEX 0.35 mg,
and sham groups, respectively. Vitreous hemorrhage was consid-
ered to be possibly related to treatment in 3.5%, 4.1%, and 0.0% of
patients, respectively (rates unadjusted for exposure), but in each
case, the vitreous hemorrhage did not require vitrectomy, and most
cleared spontaneously in a short period of time. Other ocular AEs
of interest, including retinal tear, retinal detachment, vitreous loss,
endophthalmitis, hypotony, and complication of device insertion
(implant misplacement), were reported in <2% of patients in each
group (Table 6). There were a total of 2928 DEX implant
injections during the study and 2 reports of endophthalmitis in
the study eye. One case occurred after cataract surgery and was
considered unrelated to study treatment, and the other occurred
after a DEX implant 0.7 mg injection. There were 2 cases of
implant misplacement; there was no decrease in vision in either
case.
The overall incidence of serious AEs was higher in the DEX
implant groups than in the sham group (Table 7), but was similar
among groups when the data were adjusted for treatment exposure
time. All serious AEs possibly caused by treatment were ocular
AEs in the study eye, and most were related to cataract (Table 7).Table 6. Ocular Adverse Events of Interest
AE, n (%)*
DEX Implant 0.7
mg (n [ 347)
DEX Implant 0.35
mg (n [ 343)
Sham
(n [ 350)
Retinal tear 5 (1.4) 3 (0.9) 3 (0.9)
Retinal detachment 2 (0.6) 0 2 (0.6)
Endophthalmitis 2 (0.6) 0 0
Hypotony of eye 2 (0.6) 0 0
Vitreous loss 1 (0.3) 0 0
Necrotizing retinitis 1 (0.3)y 0 0
Complication of
device insertion
1 (0.3) 1 (0.3) 0
AE ¼ adverse event; DEX implant ¼ dexamethasone intravitreal implant.
*AEs are categorized by Medical Dictionary for Regulatory Activities
(MedDRA) version 15.0 preferred terms.
yThe patient had no known history of herpes or human immunodeﬁciency
virus infection; however, the investigator considered herpes to be the most
likely cause of the retinal necrosis.The systemic serious AEs that occurred during the study are listed
in Table 8 (available at www.aaojournal.org).
Analysis of mean HbA1c and glomerular ﬁltration rate changes
from baseline showed no statistically signiﬁcant differences among
groups during the study. HbA1c mean levels remained 8.1% in
all groups (Fig 9A, available at www.aaojournal.org). Small
decreases in glomerular ﬁltration rate occurred in each group,Lens dislocation 1 (0.3) 0 0
Macular edema 1 (0.3) 0 0
Necrotizing
retinitis
1 (0.3)z 0 0
Retinal
detachment
1 (0.3) 0 0
Vitreous
adhesions
1 (0.3) 0 0
Endophthalmitis 1 (0.3) 0 0
Deathx 9 (2.6) 15 (4.4) 5 (1.4)
DEX implant ¼ dexamethasone intravitreal implant; SAE ¼ serious
adverse event.
*The SAEs are categorized by Medical Dictionary for Regulatory Activities
(MedDRA) version 15.0 preferred terms.
yIn the judgment of the investigator, there was a reasonable possibility that
the SAE was caused by the study drug, the applicator, or the insertion
procedure.
zThe patient had no known history of herpes or human immunodeﬁciency
virus infection; however, the investigator considered herpes to be the most
likely cause of the retinal necrosis.
xAll deaths were considered by the investigator to be unrelated to
treatment.
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in some patients (Fig 9B, available at www.aaojournal.org).Discussion
In this study, DEX implant 0.7 mg or 0.35 mg, with a mean
of only 4 to 5 injections over 3 years, provided robust long-
term improvement in vision and macular edema in patients
with DME. The proportion of patients with a 15-letter gain
in BCVA at the end of the study was signiﬁcantly greater
with the DEX implant compared with sham. Mean changes
in BCVA from baseline were confounded by cataract in
phakic patients after the ﬁrst year, yet signiﬁcant improve-
ment in BCVA over 3 years was still seen with DEX
implant (AUC analysis). Moreover, analysis of the propor-
tion of patients gaining 3 lines in BCVA or achieving 20/
40 vision showed separation of the DEX implant and sham
curves in study year 3, when the inﬂuence of cataract was
reduced because of cataract extractions. Visual outcomes
were favorable and the beneﬁt of DEX implant treatment
was consistent over time in pseudophakic patients. In phakic
patients who developed cataract, vision again improved with
DEX implant after cataract extraction, and there was no
increase in CRT after cataract surgery.
The safety proﬁle of the DEX implant in this study was
better than the reported safety proﬁle of other intraocular
corticosteroids in patients with DME.9,18,27 The incidence of
pressure elevations was less than reported in studies using
other steroids.28 There were no unexpected AEs, and DEX
implant demonstrated excellent systemic safety. The
overall incidence of AEs and serious AEs was similar
across treatment groups in exposure-adjusted analyses, and
there was no evidence for incremental systemic AEs or
increased risk of arterial thromboembolic events after repeat
DEX implant treatment. There were no arterial thrombo-
embolic events considered by the investigator to be related
to treatment. Also, there was no evidence of local or sys-
temic delayed wound healing.
Longer exposure to repeat DEX implant was associated
with an increase in cataract development or progression in
phakic eyes, and cataract surgery was performed in 59.2%
of phakic eyes. Lens opacities account for the reduced
improvement in BCVA seen in the DEX implant groups
after month 15 of the study. Vision improvement related to
DEX implant treatment was consistent throughout the 3-
year study in pseudophakic eyes. In phakic eyes that
developed cataract, vision improvement related to DEX
implant treatment was seen after cataract extraction, for the
remainder of the study. Increases in IOP that occurred were
typically manageable with topical medication. The timing of
IOP rises was predictable, and the incidence and magnitude
of IOP elevations did not increase upon repeated injection or
from year to year in the study. Only 2 incisional surgeries to
control steroid-induced IOP elevations were required.
Although cataract progression and IOP increases are
expected complications of corticosteroid treatment, the
incidence rates seem to differ among available intraocular
corticosteroids. The DEX implant has been associated
with a lesser incidence of increases in IOP compared with1912the intravitreal ﬂuocinolone acetonide implant or intra-
vitreal TA.28 In the 3-year phase III study of the ﬂuoci-
nolone acetonide implant in patients with DME (the
FAME study), incisional IOP-lowering surgery was per-
formed in 8.1% of patients in the high-dose group and
4.8% in the low-dose group compared with 0.5% in the
sham group.27 In comparison, in the present study, 0.6%
of patients in the DEX implant 0.7 mg group and 0.3%
in the DEX implant 0.35 mg group compared with none
in the sham group required trabeculectomy during the
study. Cataract surgery was also performed in more eyes
treated with the ﬂuocinolone acetonide implant in the
FAME study: Rates in phakic eyes were 87.2%, 80.0%,
and 27.3% in the high-dose, low-dose, and sham groups,
respectively.27
Differences in the pharmacologic and pharmacokinetic
proﬁles of the available intravitreal steroid treatments may
account for their differing safety proﬁles. Dexamethasone,
ﬂuocinolone acetonide, and TA have been shown to activate
different patterns of gene expression in human trabecular
meshwork cell lines.29 In addition, dexamethasone is less
lipophilic than TA or ﬂuocinolone acetonide and does not
accumulate to the same extent in the trabecular meshwork
and lens; therefore, there may be reduced risk of IOP
increases and cataract progression with dexamethasone.30
The MEAD study began in 2004, and the high rate of
patient discontinuations was a consequence of the study
design requirement for patients to exit before receiving any
escape treatment. The discontinuation rate was substantially
higher and patients discontinued earlier in the sham group
than in the DEX implant groups because of lack of efﬁcacy.
Long-term studies of medical treatment in DME that were
designed more recently have permitted patients to receive
escape treatment and remain in the study. For example, in the
2-year RISE/RIDE study11 of DME patients treated with
ranibizumab, which began in 2009, patients who met
predeﬁned criteria were treated with adjunctive macular
laser as well as ranibizumab or sham. The signiﬁcant
percentage of patients (72% in the sham group, 38% in the
ranibizumab 0.3 mg group, and 27% in the ranibizumab
0.5 mg group) who were treated with macular laser during
RISE/RIDE would have been exited from the MEAD
study. Also, anti-VEGF became available during the course
of the MEAD study, allowing some patients a good escape.
Because there was a bias for patients with poor outcomes in
the sham group to drop out of the study, outcomes in the
sham group were better than expected and better than is
typically seen in clinical practice. Nonetheless, DEX implant
0.7 mg and 0.35 mg demonstrated improved visual acuity
and CRT thickness compared with sham.
During the study, the protocol was modiﬁed as more
information became available about DME treatment and
DEX implant effects. One protocol amendment concerned
the timing of cataract surgery. Timely diagnosis and treat-
ment of cataracts minimizes loss of visual acuity during
corticosteroid treatment. In most cases, there was a delay of
6 months between the initial AE report of cataract and the
cataract surgery. A protocol amendment in May 2010 added
the statement that the cataract surgery should take place
within 3 months of the last retreatment, to gain the beneﬁt of
Boyer et al  Dexamethasone Intravitreal Implant for DMEDEX implant effect on reducing macular edema associated
with the cataract surgery.
Evaluation of the comparative efﬁcacy of DEX implant
versus anti-VEGF treatment will require head-to-head
studies, because of the inﬂuence of patient population
characteristics (diabetes status, baseline BCVA) and study
design (treatment frequency, use of escape therapy) on
measured efﬁcacy. Visual outcomes of ranibizumab treat-
ment in DME have been most favorable in studies that used
monthly injections (e.g., in RISE and RIDE).11 In the
RESTORE study, the BCVA stability-based retreatment
criteria resulted in patients receiving a mean of 7 ranibizu-
mab injections in year 1, and the mean average improve-
ment in BCVA during the year was 6.1 letters.31 This
improvement is similar to the mean average improvement
seen in this study in pseudophakic eyes treated with a
mean of 4 to 5 injections of DEX implant 0.7 mg (6.5
letters) or DEX implant 0.35 mg (5.9 letters) over 3 years.
This study had several limitations. An imbalance in
ischemia status at baseline may have reduced the demon-
strated efﬁcacy of DEX implant 0.7 mg relative to sham in
improving vision. The study provided no information about
use of DEX implant in combination with laser or other
treatment for DME. Also, the ﬁxed dosing schedule used
may have limited efﬁcacy, and more frequent dosing may
improve results. Patient dropout rates of approximately 20%
to 30% have been reported previously in 3-year studies of
medical treatment of DME.12,27 It is likely that the
approximately 35% discontinuation rate from the DEX
implant treatment groups in the present study was inﬂuenced
by the study design requirement for patients who received
escape treatment to exit the study.
The DEX implant demonstrated efﬁcacy in the treat-
ment of DME and had a favorable safety proﬁle in this
study. There is a need for efﬁcacious treatments for DME
in addition to anti-VEGF, because many patients do not
achieve a dry macula even after frequently repeated
treatment with anti-VEGF. The results suggest that up to
one-third of patients treated with DEX implant for their
DME achieve 20/40 vision after their ﬁrst implant, and
treatment beneﬁt is maintained over the long term when
confounding effects of cataract are removed. The small
number of injections of DEX implants associated with
clinical beneﬁt represents a substantial decrease in treat-
ment burden for patients compared with anti-VEGF ther-
apies. Cataract development or progression is probable in
phakic eyes treated with DEX implant, but cataract
removal is uneventful and is followed by clinically rele-
vant improvement in vision compared with sham treat-
ment. Prompt diagnosis and cataract extraction are needed
for optimal visual outcomes with DEX implant.
In summary, with an average of only 4 to 5 injections
over 3 years, patients treated with DEX implant achieved
statistically signiﬁcant and clinically meaningful visual im-
provements. These data support the use of DEX implant in
the management of patients with DME.
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